Asset Details
Do you wish to reserve the book?
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Do you wish to request the book?
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
2009
Overview
CDKN1C (encoding tumor suppressor p57(KIP2)) is a cyclin-dependent kinase (CDK) inhibitor whose family members are often transcriptionally downregulated in human cancer via promoter DNA methylation. In this study, we show that CDKN1C is repressed in breast cancer cells mainly through histone modifications. In particular, we show that CDKN1C is targeted by histone methyltransferase EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3), and can be strongly activated by inhibition of EZH2 in synergy with histone deacetylase inhibitor. Consistent with the overexpression of EZH2 in a variety of human cancers including breast cancer, CDKN1C in these cancers is downregulated, and breast tumors expressing low levels of CDKN1C are associated with a poor prognosis. We further show that assessing both EZH2 and CDKN1C expression levels as a measurement of EZH2 pathway activity provides a more predictive power of disease outcome than that achieved with EZH2 or CDKN1C alone. Taken together, our study reveals a novel epigenetic mechanism governing CDKN1C repression in breast cancer. Importantly, as a newly identified EZH2 target with prognostic value, it has implications in patient stratification for cancer therapeutic targeting EZH2-mediated gene repression.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Breast Neoplasms - pathology
/ Cancer
/ Cyclin-Dependent Kinase Inhibitor p57 - genetics
/ DNA
/ DNA-Binding Proteins - metabolism
/ Enhancer of Zeste Homolog 2 Protein
/ Genes
/ Genetics and Genomics/Cancer Genetics
/ Genetics and Genomics/Epigenetics
/ Genetics and Genomics/Gene Expression
/ Genetics and Genomics/Pharmacogenomics
/ Histones
/ Humans
/ Hydroxamic Acids - pharmacology
/ Kinases
/ Lysine
/ Molecular Biology/DNA Methylation
/ Molecular Biology/Histone Modification
/ Molecular Biology/Post-Translational Regulation of Gene Expression
/ Polycomb Repressive Complex 2
/ Science
/ Steroids (Organic compounds)
/ Transcription Factors - metabolism
/ Tumors
